GlassScriptPhysician profile
Annie Mathew
NPI 1346544061
$1,290.94
in general payments reported to CMS, 2019-2025
25 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $595 · 2022: $174 · 2023: $193 · 2024: $131 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.74 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $151.30 | 2022-2025 | Afrezza |
| Foundation Medicine, INC. | $148.30 | 2021 | |
| Amgen INC. | $106.95 | 2021-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $87.59 | 2021-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $73.90 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.82 | 2021-2022 | |
| Abbvie INC. | $67.30 | 2021-2024 | |
| Abbott Laboratories | $65.98 | 2021-2023 | Proclaim |
| Dexcom, INC. | $55.34 | 2021-2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $45.23 | 2021-2025 | General - Pain Management |
| Xeris Pharmaceuticals, INC. | $45.21 | 2021 | |
| Mayne Pharma Commercial LLC | $45.16 | 2021 | |
| Novo Nordisk INC | $44.99 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.88 | 2021-2022 | |
| Pfizer INC. | $39.13 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $29.48 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Sanofi-Aventis U.S. LLC | $28.05 | 2025 | |
| Lilly USA, LLC | $27.01 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $23.73 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.30 | 2022 | |
| Lucid Diagnostics INC. | $15.87 | 2022 | |
| Exact Sciences Corporation | $14.45 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $14.28 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.43 | 2022 | |
| Amarin Pharma, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.